# US 2010/0247566 A1 · Cholera vaccines

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0247566 A1
- Document ID: US20100247566A1
- Status: Published application
- Kind: A1
- Application number: 12/681,951
- Filed: 2008-10-09
- Published: 2010-09-30
- Earliest claimed: 2007-10-09
- Assignees: Tufts University
- Inventors: Andrew Camilli; Stefan Schild; Eric Jorge Nelson
- Web page: https://patentgrep.com/patent/US20100247566A1

## CPC

- A61K 39/107: {Vibrio}
- A61P 1/12: Antidiarrhoeals
- A61P 31/04: Antibacterial agents
- A61P 37/04: Immunostimulants
- A61K 2039/543: {intranasal}
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The methods and compositions of the present invention are directed to a vaccine against Vibrio cholerae comprised of V. cholerae outer membrane vesicles (OMVs). Such vaccines are relatively stable, facilitating distribution. Inventive methods generally include administration of a vaccine against Vibrio cholerae by intranasal, intraperitoneal, oral or intragastric routes. Such vaccines confer immunity to the individual, and when administered to pregnant subjects, can be conferred to the offspring of individuals.

## Claims

### Claim 1

A vaccine composition comprising outer membrane vesicles obtained from Vibrio cholerae.

### Claim 2 (depends on 1)

The vaccine composition of claim 1, wherein the Vibrio cholerae is of a strain selected from the group consisting of E7946 and O395.

### Claim 3 (depends on 1)

The vaccine composition of claim 1, wherein the Vibrio cholerae is of a mutant strain.

### Claim 4 (depends on 1)

The vaccine composition of claim 1, wherein the composition is suitable for intranasal administration.

### Claim 5 (depends on 1)

The vaccine composition of claim 1, further comprising one or more gene products not normally expressed in wild type strains of Vibrio cholerae.

### Claim 6 (depends on 5)

The vaccine composition of claim 5, wherein the one or more gene products are gene products from pathogens other than Vibrio cholerae.

### Claim 7 (depends on 6)

The vaccine composition of claim 6, wherein the one or more gene products are gene products from pathogens selected from the group consisting of Shigellae, Salmonellae enterica, Campylobacter jejuni, Helicobacter pylori, E. coli, rotavirus, and combinations thereof.

### Claim 8 (depends on 7)

The vaccine composition of claim 7, wherein the pathogens are E. coli selected from the group consisting of enterotoxigenic E. coli (ETEC), enteropathogenic E. coli (EPEC), enterohemorrhagic E. coli (EHEC), enteroinvasive E. coli (EIEC), enteroaggregative E. coli (EAggEc), and combinations thereof.

### Claim 9 (depends on 7)

The vaccine composition of claim 7, wherein the pathogens are Shigellae selected from the group consisting of Shigella dysenteriae, Shigella flexneri, Shigella boydii, Shigella sonnei, and combinations thereof.

### Claim 10

A method comprising a step of administering to an individual an effective amount of a composition comprising outer membrane vesicles obtained from Vibrio cholerae.

### Claim 11 (depends on 10)

The method of claim 10, wherein immunity from cholera is conferred to the individual.

### Claim 12 (depends on 10)

The method of claim 10, wherein immunity from cholera is conferred to one or more offspring of the individual.

### Claim 13 (depends on 10)

The method of claim 10, wherein the composition further comprises one or more gene products not normally expressed in wild type strains of Vibrio cholerae.

### Claim 14 (depends on 12)

The method of claim 12, wherein the one or more gene products are gene products from pathogens other than Vibrio cholerae.

### Claim 15 (depends on 14)

The method of claim 14, wherein the gene product are gene products from pathogens selected from the group consisting of Shigellae, Salmonellae enterica, Campylobacter jejuni, Helicobacter pylori, E. coli, rotavirus, and combinations thereof.

### Claim 16 (depends on 15)

The method of claim 15, wherein the pathogens are E. coli selected from the group consisting of enterotoxigenic E. coli (ETEC), enteropathogenic E. coli (EPEC), enterohemorrhagic E. coli (EHEC), enteroinvasive E. coli (EIEC), enteroaggregative E. coli (EAggEC), and combinations thereof.

### Claim 17 (depends on 15)

The method of claim 15, wherein the pathogens are Shigellae selected from the group consisting of Shigella dysenteriae, Shigella flexneri, Shigella boydii, Shigella sonnei, and combinations thereof.

### Claim 18 (depends on 10)

The method of claim 10, wherein the route of administration is selected from the group consisting of intranasal, oral, subcutaneous, intradermal, intramuscular, intraperitoneal, and intragastric.

### Claim 19 (depends on 18)

The method of claim 18, wherein the route of administration is intranasal.

### Claim 20 (depends on 18)

The method of claim 18, wherein the route of administration is oral.

### Claim 21

A method comprising steps of
(a) providing Vibrio cholerae cells grown in culture,
(b) preparing outer membrane vesicles from said Vibrio cholerae cells, and
(c) formulating a vaccine composition comprising said outer membrane vesicles.

### Claim 22 (depends on 21)

The method of claim 21, wherein the Vibrio cholerae cells are of a strain selected from the group consisting of E7946 and O395.

### Claim 23 (depends on 21)

The method of claim 21, wherein the vaccine composition is suitable for intranasal administration.

### Claim 24 (depends on 21)

The method of claim 21, wherein the outer membrane vesicles contain one or more gene products not normally expressed in wild type strains of Vibrio cholerae.

### Claim 25 (depends on 21)

The method of claim 21, wherein the one or more gene products are gene products from pathogenic organisms other than Vibrio cholerae.

### Claim 26 (depends on 25)

The method of claim 25, wherein the one or more gene products are gene products from pathogenic organisms selected from the group consisting of Shigellae, Salmonellae enterica, Campylobacter jejuni, Helicobacter pylori, E. coli, rotavirus, and combinations thereof.

### Claim 27 (depends on 26)

The method of claim 26, wherein the pathogens are E. coli selected from the group consisting of enterotoxigenic E. coli (ETEC), enteropathogenic E. coli (EPEC), enterohemorrhagic E. coli (EHEC), enteroinvasive E. coli (EIEC), enteroaggregative E. coli (EAggEc), and combinations thereof.

### Claim 28 (depends on 26)

The method of claim 26, wherein the pathogens are Shigellae selected from the group consisting of Shigella dysenteriae, Shigella flexneri, Shigella boydii, Shigella sonnei, and combinations thereof.
